Form 4: Zymeworks Executive Sells Shares
Insider Transaction (Form 4)
Adam Schayowitz, EVP, Head of R&D of Zymeworks Inc., sold 13,832 shares of common stock on October 9, 2026 for $25.85 per share.
Summary
- Option exercise/conversion: acquired 37,037 Common Stock on October 9, 2026; holds 37,037 after (Direct).
- Open-market sale: disposed of 13,832 Common Stock at $25.85 ($357,557) on October 9, 2026; holds 23,205 after (Direct).
- Option exercise/conversion: disposed of 37,037 Restricted Stock Unit on October 9, 2026; holds 74,074 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $357,557 of stock on the open market.
Insider Transactions
Adam Schayowitz — Officer (EVP, Head of R&D)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-09 | Option exercise/conversion | Common Stock | 37,037 | — | — | 37,037 |
| 2026-10-09 | Open-market sale | Common Stock | 13,832 | $26 | $357.6K | 23,205 |
| 2026-10-09 | Option exercise/conversion | Restricted Stock Unit | 37,037 | — | — | 74,074 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-09 | Option exercise/conversion (37,037 shares) |
| 2026-10-09 | Open-market sale (13,832 shares) |
| 2026-10-09 | Option exercise/conversion (37,037 shares) |
Keywords
insider transaction, Form 4, ZYME, Zymeworks Inc., bearish, Adam Schayowitz
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.